Table 2.

Factors associated with hepatocellular carcinoma in the absence of cirrhosis

Variables	Univariate analysis			Multivariate analysis
	OR	95%CI	P values	OR	95%CI	P values
Age > 50 yrs	0.46	0.34–0.62	< 0.0001	0.42	0.25–0.70	< 0.0001
Gender (male)	1.36	0.94–1.98	0.11
Family history of HCC	2.29	1.27–4.14	0.006	2.91	1.07–7.92	0.037
Diabetes	0.59	0.39–0.89	0.012
Hyperlipidemia	2.02	1.29–3.16	0.002
Etiology
HBV	0.79	0.54–1.13	0.19
HCV	1.43	0.92–2.22	0.12
Alcohol abuse	0.44	0.23–0.85	0.014
NAFLD	6.77	2.0–23.32	0.002
HBV-DNA ≥ 500 IU/ml	0.79	0.55–1.11	0.18
Antiviral therapy	1.04	0.69–1.57	0.86
PVTT at baseline	0.29	0.17–0.51	< 0.0001
Leukocyte counts ≥4*109/L	2.31	1.79–2.98	< 0.0001
PLT ≥100*109/L	6.23	4.31–9.02	< 0.0001	6.67	3.32–13.40	< 0.0001
AST ≥ 40 (U/L)	0.52	0.39–0.70	< 0.0001
γ-GGT ≥ 60 (U/L)	0.57	0.42–0.77	< 0.0001	0.46	0.27–0.78	0.004
TG ≥ 1.71 mmol/L	2.46	1.50–4.02	< 0.0001	2.66	1.18–6.01	0.019
PTA < 70%	0.18	0.11–0.29	< 0.0001
AFP ≥ 400 ng/ml	1.05	0.76–1.47	0.75
Child staging			< 0.0001
A	17.1	5.43–53.88	< 0.0001	5.67	1.34–24.02	0.019
B	2.48	0.73–8.40	0.15
C (Reference)
BCLC staging			< 0.0001
0-A	13.8	4.35–43.77	< 0.0001
B	10.81	3.38–34.54	< 0.0001
C	4.52	1.32–15.47	0.016
D (Reference)

Abbreviations: PTA Prothrombin activity